These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 22057187)

  • 41. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603.
    Kanemitsu Y; Kato T; Shimizu Y; Inaba Y; Shimada Y; Nakamura K; Sato A; Moriya Y;
    Jpn J Clin Oncol; 2009 Jun; 39(6):406-9. PubMed ID: 19389795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases.
    Neumann UP; Thelen A; Röcken C; Seehofer D; Bahra M; Riess H; Jonas S; Schmeding M; Pratschke J; Bova R; Neuhaus P
    Surgery; 2009 Jul; 146(1):52-9. PubMed ID: 19541010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Specific treatment situations in metastatic colorectal cancer].
    Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
    Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
    Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
    Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience.
    Cvetanovic A; Vrbic S; Filipovic S; Pejcic I; Milenkovic D; Milenkovic N; Zivkovic N
    J BUON; 2013; 18(3):641-6. PubMed ID: 24065477
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group.
    Liersch T; Meller J; Bittrich M; Kulle B; Becker H; Goldenberg DM
    Ann Surg Oncol; 2007 Sep; 14(9):2577-90. PubMed ID: 17570017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strategy for synchronous and multiple liver metastasis.
    Osada S; Imai H; Sasaki Y; Tanaka Y; Tokuyama Y; Okumura N; Nonaka K; Takahashi T; Yamaguchi K; Yoshida K
    Hepatogastroenterology; 2012; 59(113):198-203. PubMed ID: 22251539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
    Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
    Kim MS; Chung M; Ahn JB; Kim CW; Cho MS; Shin SJ; Baek SJ; Hur H; Min BS; Baik SH; Kim NK
    J Surg Oncol; 2014 Aug; 110(2):214-21. PubMed ID: 24668581
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?
    Madbouly KM; Hussein AM; Zeid A
    Dis Colon Rectum; 2013 May; 56(5):577-85. PubMed ID: 23575396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
    BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
    House MG; Kemeny NE; Gönen M; Fong Y; Allen PJ; Paty PB; DeMatteo RP; Blumgart LH; Jarnagin WR; D'Angelica MI
    Ann Surg; 2011 Dec; 254(6):851-6. PubMed ID: 21975318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases.
    Allard MA; Sebagh M; Baillie G; Lemoine A; Dartigues P; Faitot F; Faron M; Boige V; Vitadello F; Vibert E; Elias D; Adam R; Goéré D; Sa Cunha A
    Ann Surg Oncol; 2015; 22(6):1925-32. PubMed ID: 25448804
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Adjuvant chemotherapy comprising modified FOLFOX6 after curative resection of synchronous or metachronous metastasis from colorectal cancer].
    Hatano S; Ishibashi K; Amano K; Ishiguro T; Kuwabara K; Sobajima J; Ohsawa T; Okada N; Kumagai Y; Kumamoto K; Baba H; Tsuji Y; Haga N; Ishida H
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2192-4. PubMed ID: 23268020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
    Uncu D; Aksoy S; Çetin B; Yetişyiğit T; Özdemir N; Berk V; Dane F; Inal A; Harputluoğlu H; Budakoğlu B; Koca D; Sevinç A; Cihan S; Durnalı AG; Özkan M; Öztürk MA; Işıkdoğan A; Büyükberber S; Benekli M; Köş T; Alkış N; Karaca H; Turhal NS; Zengin N;
    Oncology; 2013; 84(4):240-5. PubMed ID: 23392240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.